Chronic Widespread Pain and White Blood Cell Activation

PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Widespread Chronic Pain
Interventions
DRUG

Ketotifen Fumarate

Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.

DRUG

Placebo

OTHER

Standard of Care

Trial Locations (1)

H4A 3J1

McGill University Health Centre (MUHC) - Montreal Children's Hospital, Montreal

All Listed Sponsors
collaborator

The Louise And Alan Edwards Foundation

UNKNOWN

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02984397 - Chronic Widespread Pain and White Blood Cell Activation | Biotech Hunter | Biotech Hunter